What is Cannabigerol studying for Attention-Deficit/Hyperactivity Disorder?

Cannabigerol (CBG) is being studied to see if it can reduce symptoms associated with ADHD. The trial compares the effects of a single dose of CBG to a placebo to understand its impact on attention and related indicators. The University of Arkansas is leading this research to explore potential new options for managing ADHD symptoms.

Who may be eligible for this Attention-Deficit/Hyperactivity Disorder clinical trial?

Adults aged 18 to 55 years with a diagnosis of ADHD and a minimum symptom score are eligible. Participants must not be pregnant or breastfeeding and should not have used cannabinoid products recently. They also need to meet certain health criteria and agree to avoid THC products during the study. Please review eligibility criteria for more details.

Is there any cost to participate in this Attention-Deficit/Hyperactivity Disorder clinical trial?

Study-related care, including the study drug or procedure and all trial visits, is provided at no cost. Personal travel expenses may vary and are not guaranteed to be covered. Participants should plan for their own transportation and lodging costs if needed.

Actively Recruiting

Phase 2

Age: 18Years - 55Years

All Genders

Healthy Volunteers

ID06115603

Effects of Cannabigerol on ADHD Symptoms in Adults Aged 18 to 55 A Double-Blind Placebo-Controlled Study

Led by University of Arkansas, Fayetteville · Updated on 2026-05-27

Participants Needed

Research Sites

N/A

Total Duration

AI-Summary

What this Trial Is About

Researchers are evaluating the effects of Cannabigerol CBG on symptoms associated with Attention-DeficitHyperactivity Disorder ADHD in adults aged 18 to 55 years. This phase 2 clinical trial aims to determine whether a single dose of CBG can reduce ADHD-related indicators compared to a placebo. Participants will be selected based on symptom severity and other health criteria to ensure safety and relevance. Participants will receive a single dose of either 80mg of Cannabigerol or a placebo, both administered as 1 mL during an experimental session. The placebo is made of MCT oil, while Cannabigerol is a legal, non-high-inducing cannabinoid derived from cannabis. Outcome measures will be collected at 45 minutes and 75 minutes after administration. Participants will also complete daily safety surveys for one week following the dose. Throughout the study, participants will complete several cognitive and attention tasks at 75 minutes post-dose, including the Sustained Attention to Response Task, Trail Making Test, Digit Symbol Substitution Test, Rey Auditory Verbal Learning Test, and Iowa Gambling Task. Additional assessments include mood, sleepiness, irritability, pain, anxiety, and global impressions of change. Safety monitoring involves daily surveys for one week after dosing. The total participation duration includes the experimental session plus one week of follow-up.

CONDITIONS

Brief Title

The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder

How This Trial Compares With Other Options

This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.

Factors	CBG (investigational)	Placebo (trial comparator)	Standard pharmacologic treatment
What it is	A single 80 mg dose of cannabigerol administered during one experimental session	A single 1 mL dose of placebo (MCT oil) matched to the active CBG dose	Established ADHD medications in adults include stimulants (e.g., methylphenidate, amphetamines) and non‑stimulants (e.g., atomoxetine)
Role in trial	Investigational active treatment under evaluation	Placebo control to compare with CBG effects	Represents typical first‑line pharmacologic options in usual adult ADHD care
Primary use	To assess acute effects on attention‑related cognitive tasks and ADHD‑relevant outcomes	Provides baseline comparison for cognitive and behavioral measures following administration	To reduce core ADHD symptoms over treatment course in clinical practice
How it is given or performed	Single oral administration of 80 mg CBG during an experimental session	Single oral administration of placebo (MCT oil) matched in appearance and timing	Usually taken daily as prescribed by clinicians over weeks to months
Evidence status	Effects on ADHD‑related attention task performance are currently under investigation	Serves as neutral comparator with no active effects expected	Strong evidence supports symptom reduction and improved function in adults with ADHD
Important risks	Safety profile being assessed; known safety in CBG limited to preclinical and preliminary human data	Placebo generally considered safe as inert comparator	Well‑known side effects, such as appetite loss, sleep disturbance, and cardiovascular effects for stimulants
Important limitations	Single‑dose administration limits insight into longer‑term effects	No therapeutic action; serves as a control only	Evidence supports chronic, not acute, administration—effects may differ from single‑dose CBG

Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.

Who Can Participate

Age: 18Years - 55Years

All Genders

Healthy Volunteers

Eligibility Criteria

You may qualify if you...

Between 18 and 55-years-old.
BMI between 18 and 35 kg/m2.
Score a 4 or above on the Adult ADHD Self-Report Scale (ASRS-v1.1) Symptom Checklist Part A.
Meet diagnostic criteria for ADHD with a current severity rating of at least mild as defined by the DIAMOND.
Are not pregnant or currently breastfeeding.
Have no history of significant allergic condition, hypersensitivity, or allergic reactions to cannabis, cannabinoid medications, hemp products, medium chain triglyceride oil, or peppermint.
Have not used CBG or any other cannabinoid products in the past 30 days.
Willing to abstain from using cannabis or any THC-containing product for the duration of the study.
Have never used a synthetic cannabinoid or cannabinoid analogue (e.g., dronabinol, nabilone), or a synthetic cannabinoid receptor agonist (e.g., spice, k2).
Have not been exposed to any investigational drug or device 30 days prior to screening and you have no plans to take an investigational drug during the study.
Willing to maintain a stable treatment regimen (i.e., no change in current medication use) for the duration of the study.
Not currently taking a prescription medication for ADHD and have not been prescribed a medication for ADHD in the past six months.
Not currently having thoughts of committing suicide
Does not meet criteria for current severe major depressive disorder or a substance use disorder.
Have not been diagnosed with bipolar disorder or psychosis.
Do not have an acute illness, such as a respiratory infection or other illness that would interfere with study participation; not currently taking medication for an acute illness (e.g., antibiotic).
Do not have history of diagnosis related to liver function and/or significantly impaired liver function (e.g., cirrhosis of the liver, hepatitis).
Willing to ensure they have used effective contraception (for example, oral contraception, double barrier, intra-uterine device) for 30 prior to the study and for 30 days after study completion.
Have access to a ride to the University of Arkansas campus for research appointments.
Willing to comply with current university mandates as they pertain to COVID-19 protocols (e.g., mask wearing).
Do not have any serious or unstable physical health conditions including neurological or renal illness.
Do not have any current or historical cardiovascular conditions, including hypotension, bradycardia, or heart block.
No atrial fibrillation, bradycardia, or tachycardia detected via mobile electrocardiogram during the in-laboratory visit.
No recent illicit drug use other than cannabis, or alcohol use in the 12 hours preceding the in-laboratory visit.
Not currently prescribed or taking the following medications:
- Warfarin
- Clobazam
- Valproic acid
- Phenobarbital
- Mechanistic Target of Rapamycin [mTOR] Inhibitors
- Oral tacrolimus
- St. John's wort
- Epidiolex
- Escitalopram
- Cardiovascular medications
- Strong CYP3A4 inhibitors (e.g., ketoconazole)

You will not qualify if you...

Currently pregnant or breastfeeding.
History of significant allergic conditions or reactions to cannabis, cannabinoid medications, hemp products, medium chain triglyceride oil, or peppermint.
Use of CBG or any cannabinoid products within the past 30 days.
Use of synthetic cannabinoids or receptor agonists such as dronabinol, nabilone, spice, or k2.
Exposure to investigational drugs or devices within 30 days prior to screening or plans to take investigational drugs during the study.
Changes in current medication use during the study.
Use of prescription medications for ADHD within the past six months.
Current suicidal thoughts.
Diagnosis of severe major depressive disorder or substance use disorder.
Diagnosis of bipolar disorder or psychosis.
Presence of acute illness or use of medication for acute illness.
History of liver disease or significantly impaired liver function.
Lack of effective contraception use before and after the study.
No access to transportation for research visits.
Non-compliance with COVID-19 protocols.
Serious or unstable physical health conditions including neurological or renal illness.
Cardiovascular conditions including hypotension, bradycardia, or heart block.
Detection of atrial fibrillation, bradycardia, or tachycardia during lab visit.
Recent illicit drug use other than cannabis or alcohol use within 12 hours before lab visit.
Current use of certain medications such as warfarin, clobazam, valproic acid, phenobarbital, mTOR inhibitors, oral tacrolimus, St. John's wort, Epidiolex, escitalopram, cardiovascular medications, or strong CYP3A4 inhibitors.

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - Single day

Participants receive a single dose of either 80mg Cannabigerol or placebo during an experimental session and undergo cognitive and behavioral assessments.

1 experimental session visit (in-person)

Follow-up

Duration - Up to 75 minutes post administration

Participants complete assessments 45 and 75 minutes after administration to evaluate effects on attention, mood, and other outcomes.

Assessments during the experimental session visit

Research Team

Ellen W Leen-Feldner, PhD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

Similar Trials

Pilot Study of a Remote ADHD Monitoring Program for Children...

Attention-deficit/Hyperactivity Disorder

Actively Recruiting

2 locations

Pilot Study of Digital Therapeutic NDTx-02 to Improve Execut...

Attention-Deficit/Hyperactivity Disorder

Actively Recruiting

3 locations

Study of Evening-Dosed Jornay PM Extended-Release Capsules f...

Attention-deficit/Hyperactivity Disorder

Actively Recruiting

1 location

Pilot Study of a Remote ADHD Monitoring Program for Children Aged 5 to 11 in Rural Areas

Pilot Study of Digital Therapeutic NDTx-02 to Improve Executive Function in Children and Adolescents Ages 5 to 12 With ADHD or Autism Spectrum Disorder

Study of Evening-Dosed Jornay PM Extended-Release Capsules for Adults Aged 18 to 60 with ADHD Evaluating Symptom Control, Executive Function, and Emotional Regulation Throughout the Day

Phase 4 Study of SPN-812 Viloxazine Extended-Release for Treating ADHD in Children Ages 4 to 5 Years

Study of Fibromyalgia Disease Burden in Mothers Aged 18-50 With or Without Children Diagnosed With Attention-DeficitHyperactivity Disorder

Effects of Cannabigerol on ADHD Symptoms in Adults Aged 18 to 55 A Double-Blind Placebo-Controlled Study

Washed Microbiota Transplantation to Treat ADHD Symptoms and Related Conditions in Children Aged 3 to 17

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Effects of Cannabigerol on ADHD Symptoms in Adults Aged 18 to 55 A Double-Blind Placebo-Controlled Study

On this page

Sponsors

AI-Summary

What this Trial Is About

Brief Title

How This Trial Compares With Other Options

Who Can Participate

Eligibility Criteria

Your Study Journey

Research Team

How is the study designed?

Similar Trials

Pilot Study of a Remote ADHD Monitoring Program for Children...

Pilot Study of Digital Therapeutic NDTx-02 to Improve Execut...

Study of Evening-Dosed Jornay PM Extended-Release Capsules f...

Frequently Asked Questions

What is Cannabigerol studying for Attention-Deficit/Hyperactivity Disorder?

Who may be eligible for this Attention-Deficit/Hyperactivity Disorder clinical trial?

Is there any cost to participate in this Attention-Deficit/Hyperactivity Disorder clinical trial?

Will I receive Cannabigerol or a placebo?

What tests will measure changes in my ADHD symptoms during the trial?

What happens after this Attention-Deficit/Hyperactivity Disorder clinical trial ends?

Can I leave this Attention-Deficit/Hyperactivity Disorder clinical trial if I change my mind?

Not the Right Trial for You?

On this page

Sponsors

Sponsors

How This Trial Compares With Other Options

Who Can Participate

Eligibility Criteria

Your Study Journey

How is the study designed?

Similar Trials

Pilot Study of a Remote ADHD Monitoring Program for Children...

Pilot Study of Digital Therapeutic NDTx-02 to Improve Execut...

Study of Evening-Dosed Jornay PM Extended-Release Capsules f...

Frequently Asked Questions

What is Cannabigerol studying for Attention-Deficit/Hyperactivity Disorder?

Who may be eligible for this Attention-Deficit/Hyperactivity Disorder clinical trial?

Is there any cost to participate in this Attention-Deficit/Hyperactivity Disorder clinical trial?

Will I receive Cannabigerol or a placebo?

What tests will measure changes in my ADHD symptoms during the trial?

What happens after this Attention-Deficit/Hyperactivity Disorder clinical trial ends?

Can I leave this Attention-Deficit/Hyperactivity Disorder clinical trial if I change my mind?

Sponsors